tldrdailynews.com logo

Vanda Pharmaceuticals' NEREUS™ Gains FDA Approval for Motion Sickness Prevention

1 min read
Source: PR Newswire
Vanda Pharmaceuticals' NEREUS™ Gains FDA Approval for Motion Sickness Prevention
Photo: PR Newswire
TL;DR

Vanda Pharmaceuticals received FDA approval for NEREUS (tradipitant), the first new drug in over 40 years for preventing motion sickness-induced vomiting, supported by robust clinical trial data showing significant efficacy and safety, marking a major advancement in treatment options for this condition affecting millions.

Topics:businesshealthcare#fda-approval#healthcare#motion-sickness#nereus#tradipitant#vomiting-prevention
Share this article
  1. Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness  PR Newswire
  2. VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains  Yahoo Finance
  3. Stock Movers: Vanda, Nike, Year in Review  Bloomberg.com
  4. US FDA approves Vanda Pharmaceuticals' motion sickness drug  Reuters
  5. Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin  Seeking Alpha

Want the full story? Read the original reporting

Read on PR Newswire